Search - tctmd.com

Displaying 401 - 420 of 496

Sort: Relevancy | Date

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

La Evaluación de la FFR Contra la Enfermedad de los Vasos Pequeños Mejora los Resultados

L.A. McKeown

March 23, 2012

News Daily News

FFR Assessment for Small Vessel Disease Improves Outcomes

L.A. McKeown

March 23, 2012

News Industry News

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

March 20, 2012

News Industry News

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

March 20, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

Jason Kahn

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Presenter: C. Von Birgelen

February 20, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Advertisement

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

La Evaluación de la FFR Contra la Enfermedad de los Vasos Pequeños Mejora los Resultados

FFR Assessment for Small Vessel Disease Improves Outcomes

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

SCAAR: Second-Generation DES Improve Hard Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content